Report Update Mar 1, 2026

Hungary - Medicaments Containing Insulin But not Antibiotics in Measured Doses - Market Analysis, Forecast, Size, Trends and Insights

Single report

Sent by email within 24h (Mon-Fri)

$599 Basic Edition

$2095 Professional Edition

What's the difference?

Subscription

Online access and download

from $350/month

Get instant access to more than 2 million reports, dashboards, and datasets on the IndexBox Platform.

View Pricing

Hungary: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2026

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Hungary

The Hungarian prophylactic medicaments containing insulin market was finally on the rise to reach $X in 2025, after three years of decline. Over the period under review, consumption recorded a measured increase. Over the period under review, the market attained the peak level at $X in 2020; however, from 2021 to 2025, consumption failed to regain momentum.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Hungary

In value terms, prophylactic medicaments containing insulin production reached $X in 2025 estimated in export price. Over the period under review, production showed a perceptible decrease. The most prominent rate of growth was recorded in 2018 when the production volume increased by X%. Prophylactic medicaments containing insulin production peaked at $X in 2012; however, from 2013 to 2025, production remained at a lower figure.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports from Hungary

In 2025, overseas shipments of medicaments containing insulin but not antibiotics in measured doses decreased by X% to X tons for the first time since 2016, thus ending a seven-year rising trend. Overall, exports, however, posted notable growth. The most prominent rate of growth was recorded in 2021 when exports increased by X% against the previous year. Over the period under review, the exports reached the peak figure at X tons in 2023, and then declined remarkably in the following year.

In value terms, prophylactic medicaments containing insulin exports contracted to $X in 2025. In general, exports, however, continue to indicate notable growth. The pace of growth appeared the most rapid in 2021 with an increase of X% against the previous year. The exports peaked at $X in 2023, and then fell in the following year.

Exports by Country

Slovenia (X tons), Romania (X tons) and Ukraine (X tons) were the main destinations of prophylactic medicaments containing insulin exports from Hungary, together comprising X% of total exports.

From 2012 to 2025, the most notable rate of growth in terms of shipments, amongst the main countries of destination, was attained by Slovenia (with a CAGR of X%), while the other leaders experienced more modest paces of growth.

In value terms, the largest markets for prophylactic medicaments containing insulin exported from Hungary were Slovenia ($X), Romania ($X) and Ukraine ($X), with a combined X% share of total exports. Georgia, Azerbaijan, Denmark and Bulgaria lagged somewhat behind, together accounting for a further X%.

Azerbaijan, with a CAGR of X%, saw the highest growth rate of the value of exports, among the main countries of destination over the period under review, while shipments for the other leaders experienced more modest paces of growth.

Export Prices by Country

The average prophylactic medicaments containing insulin export price stood at $X per ton in 2025, with an increase of X% against the previous year. Over the period under review, the export price recorded a relatively flat trend pattern. The pace of growth appeared the most rapid in 2016 an increase of X% against the previous year. The export price peaked at $X per ton in 2021; however, from 2022 to 2025, the export prices stood at a somewhat lower figure.

There were significant differences in the average prices for the major foreign markets. In 2025, amid the top suppliers, the country with the highest price was Denmark ($X per ton), while the average price for exports to Georgia ($X per ton) was amongst the lowest.

From 2012 to 2025, the most notable rate of growth in terms of prices was recorded for supplies to Denmark (X%), while the prices for the other major destinations experienced more modest paces of growth.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports into Hungary

After two years of growth, supplies from abroad of medicaments containing insulin but not antibiotics in measured doses decreased by X% to X tons in 2025. Over the period under review, total imports indicated a moderate increase from 2012 to 2025: its volume increased at an average annual rate of X% over the last twelve years. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. The most prominent rate of growth was recorded in 2013 with an increase of X%. Imports peaked at X tons in 2020; however, from 2021 to 2025, imports remained at a lower figure.

In value terms, prophylactic medicaments containing insulin imports reduced to $X in 2025. In general, imports, however, showed a relatively flat trend pattern. The most prominent rate of growth was recorded in 2017 with an increase of X% against the previous year. Over the period under review, imports hit record highs at $X in 2020; however, from 2021 to 2025, imports stood at a somewhat lower figure.

Imports by Country

In 2025, Germany (X tons) constituted the largest prophylactic medicaments containing insulin supplier to Hungary, accounting for a X% share of total imports. Moreover, prophylactic medicaments containing insulin imports from Germany exceeded the figures recorded by the second-largest supplier, Denmark (X tons), sixfold.

From 2012 to 2025, the average annual growth rate of volume from Germany stood at X%. The remaining supplying countries recorded the following average annual rates of imports growth: Denmark (X% per year) and France (X% per year).

In value terms, Germany ($X) constituted the largest supplier of medicaments containing insulin but not antibiotics in measured doses to Hungary, comprising X% of total imports. The second position in the ranking was taken by Denmark ($X), with a X% share of total imports.

From 2012 to 2025, the average annual rate of growth in terms of value from Germany totaled X%. The remaining supplying countries recorded the following average annual rates of imports growth: Denmark (X% per year) and France (X% per year).

Import Prices by Country

The average prophylactic medicaments containing insulin import price stood at $X per ton in 2025, approximately reflecting the previous year. Overall, the import price saw a noticeable decrease. The pace of growth appeared the most rapid in 2017 an increase of X%. Over the period under review, average import prices attained the peak figure at $X per ton in 2012; however, from 2013 to 2025, import prices stood at a somewhat lower figure.

There were significant differences in the average prices amongst the major supplying countries. In 2025, amid the top importers, the country with the highest price was Denmark ($X per ton), while the price for Germany ($X per ton) was amongst the lowest.

From 2012 to 2025, the most notable rate of growth in terms of prices was attained by Germany (X%), while the prices for the other major suppliers experienced a decline.

Frequently Asked Questions (FAQ) :

What are the largest markets for medicaments containing insulin but not antibiotics in measured doses in the world?

The countries with the highest volumes of consumption in 2024 were Denmark, India and Brazil, together comprising 43% of global consumption.

What are the largest producers of medicaments containing insulin but not antibiotics in measured doses in the world?

The countries with the highest volumes of production in 2024 were India, Denmark and France, with a combined 65% share of global production. Ireland, Brazil, Italy and China lagged somewhat behind, together accounting for a further 32%.

What are the leading suppliers of medicaments containing insulin but not antibiotics in measured doses to Hungary?

In value terms, Germany constituted the largest supplier of medicaments containing insulin but not antibiotics in measured doses to Hungary, comprising 71% of total imports. The second position in the ranking was taken by Denmark, with a 22% share of total imports.

What are the leading importers of medicaments containing insulin but not antibiotics in measured doses from Hungary?

In value terms, the largest markets for prophylactic medicaments containing insulin exported from Hungary were Slovenia, Romania and Ukraine, together accounting for 92% of total exports. Georgia, Azerbaijan, Denmark and Bulgaria lagged somewhat behind, together comprising a further 7.1%.

What is the average export price for medicaments containing insulin but not antibiotics in measured doses in Hungary?

The average prophylactic medicaments containing insulin export price stood at $188,652 per ton in 2024, with an increase of 6.1% against the previous year. Over the period under review, the export price recorded a relatively flat trend pattern. The most prominent rate of growth was recorded in 2016 an increase of 21%. Over the period under review, the average export prices reached the peak figure at $194,319 per ton in 2021; however, from 2022 to 2024, the export prices remained at a lower figure.

What is the average import price for medicaments containing insulin but not antibiotics in measured doses in Hungary?

In 2024, the average prophylactic medicaments containing insulin import price amounted to $209,911 per ton, standing approx. at the previous year. Overall, the import price recorded a perceptible descent. The pace of growth appeared the most rapid in 2017 an increase of 8.1%. Over the period under review, average import prices hit record highs at $323,177 per ton in 2012; however, from 2013 to 2024, import prices failed to regain momentum.

This report provides a comprehensive view of the prophylactic medicaments containing insulin industry in Hungary, tracking demand, supply, and trade flows across the national value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.

Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between domestic suppliers and international partners. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the prophylactic medicaments containing insulin landscape in Hungary.

Key findings

Domestic demand is shaped by both household and industrial usage, with trade flows linking local supply to imports and exports.
Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions.
Supply depends on input availability and production efficiency, creating a distinct national cost curve.
Market concentration varies by segment, creating different competitive landscapes and entry barriers.
The 2035 outlook highlights where capacity investment and demand growth are most aligned within the country.

Report scope

The report combines market sizing with trade intelligence and price analytics for Hungary. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts.

Market size and growth in value and volume terms
Consumption structure by end-use segments
Production capacity, output, and cost dynamics
Trade flows, exporters, importers, and balances
Price benchmarks, unit values, and margin signals
Competitive context and market entry conditions

Product coverage

Prodcom 21201260 - Medicaments containing insulin but not antibiotics, for therapeutic or prophylactic uses, put up in measured doses or for retail sale

Country coverage

Hungary

Country profile and benchmarks

This report provides a consistent view of market size, trade balance, prices, and per-capita indicators for Hungary. The profile highlights demand structure and trade position, enabling benchmarking against regional and global peers.

Methodology

The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.

International trade data (exports, imports, and mirror statistics)
National production and consumption statistics
Company-level information from financial filings and public releases
Price series and unit value benchmarks
Analyst review, outlier checks, and time-series validation

All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.

Forecasts to 2035

The forecast horizon extends to 2035 and is based on a structured model that links prophylactic medicaments containing insulin demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts in Hungary.

Historical baseline: 2012-2025
Forecast horizon: 2026-2035
Scenario-based sensitivity to income growth, substitution, and regulation
Capacity and investment outlook for major producing companies

Each projection is built from national historical patterns and the broader regional context, allowing the report to show where growth is concentrated and where risks are elevated.

Price analysis and trade dynamics

Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.

Price benchmarks by country and sub-region
Export and import unit value trends
Seasonality and calendar effects in trade flows
Price outlook to 2035 under baseline assumptions

Profiles of market participants

Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.

Business focus and production capabilities
Geographic reach and distribution networks
Cost structure and pricing strategy indicators
Compliance, certification, and sustainability context

How to use this report

Quantify domestic demand and identify the most attractive segments
Evaluate export opportunities and prioritize target destinations
Track price dynamics and protect margins
Benchmark performance against leading competitors
Build evidence-based forecasts for investment decisions

This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of prophylactic medicaments containing insulin dynamics in Hungary.

FAQ

What is included in the prophylactic medicaments containing insulin market in Hungary?

The market size aggregates consumption and trade data, presented in both value and volume terms.

How are the forecasts to 2035 built?

The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.

Does the report cover prices and margins?

Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.

Which benchmarks are included?

The report benchmarks market size, trade balance, prices, and per-capita indicators for Hungary.

Can this report support market entry decisions?

Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.

1. INTRODUCTION

Making Data-Driven Decisions to Grow Your Business
1. REPORT DESCRIPTION
2. RESEARCH METHODOLOGY AND THE AI PLATFORM
3. DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
4. GLOSSARY AND SPECIFIC TERMS
2. EXECUTIVE SUMMARY

A Quick Overview of Market Performance
1. KEY FINDINGS
2. MARKET TRENDSThis Chapter is Available Only for the Professional EditionPRO
3. MARKET OVERVIEW

Understanding the Current State of The Market and its Prospects
1. MARKET SIZE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. MARKET STRUCTURE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
3. TRADE BALANCE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
4. PER CAPITA CONSUMPTION: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
5. MARKET FORECAST TO 2035
4. MOST PROMISING PRODUCTS FOR DIVERSIFICATION

Finding New Products to Diversify Your Business
- This Chapter is Available Only for the Professional EditionPRO
1. TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
2. BEST-SELLING PRODUCTS
3. MOST CONSUMED PRODUCTS
4. MOST TRADED PRODUCTS
5. MOST PROFITABLE PRODUCTS FOR EXPORTS
5. MOST PROMISING SUPPLYING COUNTRIES

Choosing the Best Countries to Establish Your Sustainable Supply Chain
- This Chapter is Available Only for the Professional EditionPRO
1. TOP COUNTRIES TO SOURCE YOUR PRODUCT
2. TOP PRODUCING COUNTRIES
3. TOP EXPORTING COUNTRIES
4. LOW-COST EXPORTING COUNTRIES
6. MOST PROMISING OVERSEAS MARKETS

Choosing the Best Countries to Boost Your Export
- This Chapter is Available Only for the Professional EditionPRO
1. TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
2. TOP CONSUMING MARKETS
3. UNSATURATED MARKETS
4. TOP IMPORTING MARKETS
5. MOST PROFITABLE MARKETS
7. PRODUCTION

The Latest Trends and Insights into The Industry
1. PRODUCTION VOLUME AND VALUE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
8. IMPORTS

The Largest Import Supplying Countries
1. IMPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. IMPORTS BY COUNTRY: HISTORICAL DATA (2012–2025)
3. IMPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025)
9. EXPORTS

The Largest Destinations for Exports
1. EXPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
2. EXPORTS BY COUNTRY: HISTORICAL DATA (2012–2025)
3. EXPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025)
10. PROFILES OF MAJOR PRODUCERS

The Largest Producers on The Market and Their Profiles
- This Chapter is Available Only for the Professional EditionPRO
LIST OF TABLES
1. Key Findings In 2025
2. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
3. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
4. Per Capita Consumption: Historical Data (2012–2025) and Forecast (2026–2035)
5. Imports, In Physical Terms, By Country, 2012–2025
6. Imports, In Value Terms, By Country, 2012–2025
7. Import Prices, By Country, 2012–2025
8. Exports, In Physical Terms, By Country, 2012–2025
9. Exports, In Value Terms, By Country, 2012–2025
10. Export Prices, By Country, 2012–2025
LIST OF FIGURES
1. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
2. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
3. Market Structure – Domestic Supply vs. Imports, in Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
4. Market Structure – Domestic Supply vs. Imports, in Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
5. Trade Balance, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
6. Trade Balance, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
7. Per Capita Consumption: Historical Data (2012–2025) and Forecast (2026–2035)
8. Market Volume Forecast to 2035
9. Market Value Forecast to 2035
10. Market Size and Growth, By Product
11. Average Per Capita Consumption, By Product
12. Exports and Growth, By Product
13. Export Prices and Growth, By Product
14. Production Volume and Growth
15. Exports and Growth
16. Export Prices and Growth
17. Market Size and Growth
18. Per Capita Consumption
19. Imports and Growth
20. Import Prices
21. Production, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
22. Production, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
23. Imports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
24. Imports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
25. Imports, In Physical Terms, By Country, 2025
26. Imports, In Physical Terms, By Country, 2012–2025
27. Imports, In Value Terms, By Country, 2012–2025
28. Import Prices, By Country, 2012–2025
29. Exports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
30. Exports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
31. Exports, In Physical Terms, By Country, 2025
32. Exports, In Physical Terms, By Country, 2012–2025
33. Exports, In Value Terms, By Country, 2012–2025
34. Export Prices, By Country, 2012–2025

Mar 19, 2026

Branded Pharma Sector Reports Mixed Q4 2025 Results

An analysis of Q4 2025 earnings reveals the branded pharmaceutical sector posted mixed results, missing revenue estimates. While Eli Lilly and Zoetis outperformed, the sector faces patent cliffs and regulatory pressures.

Mar 18, 2026

Weight Loss Drug Market: Eli Lilly Leads, Viking Therapeutics Emerges as Key Competitor

Analysis of the high-growth weight loss drug market, detailing Eli Lilly's leadership, the race for oral treatments, and Viking Therapeutics' competitive potential based on recent positive trial data.

Mar 3, 2026

Wall Street Analysts Adjust Ratings on Block, Palo Alto Networks, MongoDB, and Others

Overview of recent analyst rating adjustments on several companies, detailing key upgrades and downgrades based on earnings, guidance, and market conditions.

Feb 5, 2026

Eli Lilly Projects 2026 Profit Above Estimates Fueled by Obesity Drug Demand

Eli Lilly projects its 2026 profit will exceed analyst estimates, fueled by surging demand for obesity treatments like Zepbound and the upcoming launch of an oral weight-loss pill.

Jan 31, 2026

Eli Lilly Building $3.5 Billion Pharmaceutical Plant in Pennsylvania for Injectable Drugs

Eli Lilly is constructing a $3.5B plant in Pennsylvania to boost production of injectable obesity and diabetes drugs like retatrutide, part of its major domestic expansion.

Jan 7, 2026

Healthcare Stocks: Sector Gains 19.9% with AbbVie, Insulet, Cencora Highlighted

Healthcare sector outperforms S&P 500 by 9.1 percentage points with 19.9% gains. Analysis identifies three resilient stocks—AbbVie, Insulet, and Cencora—amid innovation and regulatory caution.

G2 reviews

Teams rate IndexBox on G2

Verified reviewers highlight faster qualification, clearer collaboration, and stronger bid readiness.

High Performer

Regional Grid

High Performer Small-Business

Grid Report

Leader Small-Business

Grid Report

High Performer Mid-Market

Grid Report

Leader

Grid Report

Users Love Us

Milestone badge

★ ★ ★ ★ ★

5/5

Great for Market Insights and Analysis

“IndexBox is a solid source for trade and industrial market data — what I like best about it is how it aggregates official statistics.”